Clinical Study Shows Monteloeder's Rosemary and Grapefruit Composition Helps Maintain Youthful-Looking Skin Under UV Exposure
The study published in April 2025 in the International Journal of Molecular Sciences, authored by Pau Navarro and colleagues first analyzed in vitro the photoprotective potential of Nutroxsun® on UVR-exposed human dermal fibroblasts. These results highlighted the composition's capacity to help reduce markers of oxidative stress, inflammation, and processes associated with the degradation of the skin's structural integrity. Results were expressed through the reduction of inflammatory markers, ROS, and the modulation of matrix metalloproteinases (MMPs)—enzymes involved in the breakdown of structural matrix components such as collagen and elastin fibers.
Photoaging is associated with a reduction in collagen and elastin production resulting from repeated exposure to UVR. Collagen provides the skin's support matrix and is a key determinant for the preservation of skin firmness and elasticity. UV exposure is known to accelerate the generation of reactive oxygen species (ROS), which contribute to oxidative stress that may impact DNA. This may lead to redness in the short term and can contribute to collagen degradation over time with exposure to both UVA and UVB radiation. This process may ultimately result in wrinkles and loss of skin structure.
Nutroxsun® is a proprietary combination of extracts of rosemary ( Rosmarinus officinalis ) and grapefruit ( Citrus paradise ) created by the nutraceutical company Monteloeder to affect an inside-out approach to supporting skin health and maintaining youthful looking skin challenged by everyday environmental stressors such as prolonged sun exposure.
MADRID, May 7, 2025 /PRNewswire/ -- Monteloeder, SL, a subsidiary of SUANNUTRA SA, announces exciting results from a new clinical study regarding its natural, beauty-from-within formulation Nutroxsun®. The results of the two-phase trial bolster scientific support for Nutroxsun ®'s role in helping maintain skin integrity and a youthful appearance when exposed to environmental stressors such as ultraviolet (UV) radiation. Nutroxsun® will be presented at Vitafoods Europe, Barcelona, on May 20-22, 2025, Booth #3K22.
Story Continues
"Skin redness are the most noticeable and immediate inflammatory reaction to solar radiation," explains Nuria Caturla, Chief R&D Officer at Monteloeder. "It usually appears 3–5 hours after exposure and peaks at 12–24 hours, fading gradually over 72 hours."
The study participants took either 100mg or 250mg of the botanical formula, or a placebo. All participants experienced increased skin redness 24 hours after UVB exposure, confirming an erythemal response. However, those who took Nutroxsun® showed a milder increase in redness. Redness increased by 62.7% in the placebo group, compared to 44.7% in the Nutroxsun® 100mg group, and just 41.0% in the 250mg group. Both the 100mg and 250mg doses led to significantly less redness 24 hours after UV exposure.
By 72 hours, redness in both Nutroxsun® groups had nearly returned to baseline, while the placebo group still showed elevated levels, indicating slower recovery. Among fair-skinned participants the 250mg dose was more effective in supporting skin recovery than 100mg,with lower redness observed at all time points. Although the 100mg dose also demonstrated a measurable benefit.
"Nutroxsun® was developed as a dietary solution to support the skin's natural defense mechanisms in response to UV-induced oxidative stress," affirms Mariana Ortega, Science Marketing Manager of SUANNUTRA. "It acts from within to help maintain skin health when exposed to environmental aggressors. Rosemary and grapefruit extracts contain phenolic compounds that work synergistically to help neutralize free radicals generated by UV exposure. These effects are relevant to both short-term/ immediate responses, such as redness, and long-term factors associated with visible signs of photoaging, including collagen and elastin changes."
"The results from the present study reinforce and expand on previous evidence supporting Nutroxsun®'s role in helping improve skin health and appearance when exposed to UV-related stressors," adds Caturla. "Rosemary extracts have been shown to help slow down collagen degradation further highlighting their potential to support dermal structure and resilience. Grapefruit flavones have been studied for their role in counteracting UVB-induced oxidative effects that may impact collagen integrity helping protect the skin by stopping UVB rays from breaking down collagen."
This study serves as a follow-up to the encouraging results observed in previous preclinical and clinical trials. A clinical trial, involving 90 participants over a period of two months, resulted in a reduction in markers of skin lipid peroxidation associated with UVB and UVA exposure, and perceived improvements in skin texture, wrinkles and elasticity. In this trial, the participants said they found their skin to "feel more moisturized." More than three-quarters (77%) noticed an improved skin appearance and more even skin tone. Nearly that many participants (73%) said their skin "felt firmer," and almost two-thirds (60%) observed a visible reduction in appearance of wrinkles.
Join us at Vitafoods, booth #3K22 to discover exciting opportunities together.
About Monteloeder
Monteloeder contributes cutting-edge innovation and scientific rigor to the development of botanical health ingredients, featuring proprietary patented products supported by clinical studies. The company's portfolio has garnered international accolades in wellness, women health, and beauty from within. Monteloeder is a subsidiary of SUANNUTRA, which boasts a rich heritage of more than 125 years of combined experience in the European, US, and Asian nutraceutical sector.
About SUANNUTRA
SUANNUTRA, SA is a leading provider of functional and branded ingredients to the nutraceutical market. It operates as the hub of three nutraceutical companies with a global presence: SuanNutra, Inc. (US), Gonmisol, SA (Europe), and Monteloeder (international). Each of these entities possesses unique capabilities to cater to their respective markets. With more than 125 years of combined experience, SUANNUTRA serves 1,500 customers in 50 countries.
Press Contact
NutriPR
Liat Simha
Tel: +972-9-9742893
E-mail: liat@nutripr.com
Twitter: @NutriPR_
Website: www.nutripr.com
Company contact
Monteloeder, S.L., a subsidiary of SuanNutra
Mariana Ortega
Science Marketing Manager
E-mail: info@monteloeder.com
Website: www.suannutra.com
Photo: https://mma.prnewswire.com/media/2681269/Monteloeder_Formulation.jpg
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/clinical-study-shows-monteloeders-rosemary-and-grapefruit-composition-helps-maintain-youthful-looking-skin-under-uv-exposure-302448417.html
SOURCE Monteloeder, S.L.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. ('Sonendo' or the 'Company') (OTC Pink: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the promotion of John McGaugh to Chief Operating Officer. Mr. McGaugh previously held the position of Senior Vice President of Operations. 'Since Sonendo embarked on its strategic reset in early-2024, the Company has stabilized revenue, generated significant leverage in gross margin, and meaningfully lowered total operating expenses, adjusted EBITDA loss and cash burn,' stated Bjarne Bergheim, President and Chief Executive Officer of Sonendo. 'John has been a significant contributor to all those improvements, and we expect he will continue to drive additional operating leverage as the Company continues to execute its plans to achieve profitability. John is a valuable member of the team, and I am excited to see him take on the role of Chief Operating Officer.' In addition to his previous responsibilities overseeing quality, manufacturing, supply chain, and technical services operations, Mr. McGaugh now has oversight of Sonendo's capital and consumables sales teams and commercial operations. Mr. McGaugh has over 20 years overseeing global manufacturing operations. He joined Sonendo in May 2023 and has been instrumental in leading significant operational efficiencies with console assembly and procedure instrument margin contributions. Prior to his time at Sonendo, Mr. McGaugh served as a multi-site operational leader for Abbott Vascular. In addition to his experience at Abbott, Mr. McGaugh has held leadership roles at Boston Scientific and American Medical Systems. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. For more information about Sonendo and the GentleWave System, please visit To find a GentleWave doctor in your area, please visit Forward Looking Statements This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's ability to continue to drive additional operating leverage and/or execute its plans to achieve profitability, whether as a result of Mr. McGaugh or otherwise. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in the 'Risk Factors' section of the Company's Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025. Such filings are available at The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Yahoo
an hour ago
- Yahoo
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive disease following prior therapy.1 This indication was approved based on five open-label, non-randomized clinical trials conducted in the U.S. (ONC006 [NCT02525692], ONC013 [NCT03295396], ONC014 [NCT03416530], ONC016 [NCT05392374], and ONC018 [NCT03134131]).1 'Onco360 is grateful for the opportunity to add Modeyso™ to our expansive portfolio of cancer and rare disease therapies as the first and only FDA-approved treatment for pediatric and adult patients with diffuse midline glioma,' said Benito Fernandez. 'We are proud and humbled to be part of this innovative treatment in support of patients, caregivers and families impacted by this devastating disease.' Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.1 The efficacy of Modeyso was evaluated in an integrated efficacy population of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label, non-randomized clinical trials.1 The primary outcome was overall response rate (ORR) of 22% (95% CI: 12,36). The trial also demonstrated a duration of response of 10.3 months (95% CI: 7.3, 15.2) with 73% maintaining their response for at least six months and 27% for at least 12 months.1 Dordaviprone demonstrated manageable safety and tolerability adverse events. The most common adverse reactions (≥20 %; all causality) experienced with dordaviprone were fatigue, headache, nausea, vomiting, and musculoskeletal pain.1 Please see the full Prescribing Information for Modeyso. About Onco360 Oncology Pharmacy:Onco360 is the nation's largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Media Contact: Benito Fernandez, Chief Commercial References:1Modeyso™ (Dordaviprone) [Package Insert]. Palo Alto, CA. Jazz Pharmaceuticals. in to access your portfolio
Business Wire
3 hours ago
- Business Wire
Polio Vaccination Campaign Planned in Afghanistan with PharmaJet
GOLDEN, Colo.--(BUSINESS WIRE)--Please replace the release dated August 19, 2025 with the following corrected version due to multiple revisions - removing mentions of WHO and UNICEF and all operational details which are subject to national authorities and partners agreement. The updated release reads: Polio Vaccination Campaign Planned in Afghanistan with PharmaJet ® Tropis ® ID Delivery System PharmaJet has been awarded a tender to support the first large-scale implementation of intradermal (ID) polio immunization in Afghanistan. PharmaJet's award builds on the successful implementation of Tropis for ID delivery in polio vaccination campaigns in Pakistan, Nigeria, and Somalia. The use of Tropis ID in polio vaccination campaigns has improved vaccine coverage, decreased immunization program costs, and increased acceptability. PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign in Afghanistan. Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. Including Tropis ID fractional doses of inactivated polio vaccine (fIPV) in this immunization program supports Afghanistan's polio eradication goals to eliminate persistent virus lineages, prevent new WPV1 cases, and prevent local transmission. 'We are pleased to be supporting Afghanistan in their continued efforts to eradicate polio,' said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. 'We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability 1 previously seen with Tropis ID delivered fIPV in Pakistan, 1 Somalia, 2 and Nigeria 3.' Refer to Instructions for Use to ensure safe injections and to review risks. *NOTE: We regret that the content of this news release on August 19, 2025 was originally published without UNICEF/WHO consent. Operational details remain subject to national authorities and partners agreement. 1 Daly, C et al, Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, Vaccine, Volume 38 Issue 8, 18 February, 2020, Pages 1893-1898 2 Nouh, K et al, Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia, Springer Nature Volume 2 article number 16 (2024) 3 Biya, O et al, Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022, CDC Morbidity and Mortality Weekly report, November 24, 2023 / 72(47);1290–1291 About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn.
